Sun Pharmaceutical Industries Ltd.
Fundamentals
- Market cap
- ₹4.47 lakh cr
- P/E
- 38.93×
- ROE
- 15.13%
- Debt / equity
- 0.03
- Div yield
- 0.85%
- 52-week range
- 1548.00 — 1916.60
Company snapshot
Sun Pharmaceutical Industries Ltd.
Pharmaceuticals
₹4.47 L cr
P/E 38.92×
Latest quarter · Mar 2026
Sales₹14,612 cr
Net profit₹2,724 cr
Op. margin+27.1%
EPS₹11.31
Strength & growth
Debt / equity0.03×
Current ratio2.89×
Sales CAGR+7.5%
EPS CAGR+9.6%
The timeline — 5 notes on Sun Pharmaceutical Industries Ltd.
May 2026
- 26 May 26 · 6:25 PM IST Lead Lead · Mega cap
Sun Pharma reports durable response for UNLOXCYT in skin cancer trial
Long-term data from a trial shows a 50% objective response rate for UNLOXCYT in locally advanced cutaneous squamous cell carcinoma.
- 22 May 26 · 7:47 PM IST Brief Brief · Mega cap
Sun Pharma's US innovation revenue overtakes its generics business
Innovative medicine sales hit $1.1B in FY26, but Q4 margins felt the pinch of higher spending and lower milestone income.
- 22 May 26 · 3:04 PM IST Brief Brief · Earnings · Mega cap
Sun Pharma posts 26% Q4 profit growth and readies tax shift
The drugmaker closed FY26 with a ₹5 final dividend, while preparing to tap a lower tax regime in the new fiscal year.
- 22 May 26 · 2:56 PM IST Brief Brief · Earnings · Mega cap
Sun Pharmaceutical FY26 growth hits 11.9% as dividends hold steady
A routine year-end filing shows consolidated sales growth and a final ₹5 dividend, maintaining the total payout from the prior year.